Dose escalation to combat hypoxia in prostate cancer: A radiobiological study on clinical data

British Journal of Radiology

Volumn 79, Issue 947, 2006, Pages 905-911

  Wang, Jian Z ^a   Li, X A ^b   Mayr, N A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONFIDENCE INTERVAL; DOSE CALCULATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HUMAN CELL; HYPOXIA; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; MALE; MATHEMATICAL COMPUTING; OXYGEN ENHANCEMENT RATIO; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOBIOLOGY;

ANOXIA; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33751232289     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/18700614     Document Type: Article

References (45)

1. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle Po2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9.
2. Movsas B, Chapman JD, Greenberg RE, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age. Cancer 2000;89:2018-24.
3. Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999;53:11-8.
4. Parker CP, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
5. Okunieff P, Hoeckel M, Dunphy EP, et al. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 1993;26:631-6.
6. Höckel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
7. Höckel M, Schlenger K, Mitze M, et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996;6:3-9.
8. Nordsmark M, Overgaard M, Overgaard J. Oxygenation status predicts radiation response in advanced squamous cell carcinoma of head and neck. Radiother Oncol 1996;41:31-9.
9. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 1997;38:285-9.
10. Hall EJ. Radiobiology for the radiologist. 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2000:91-111.
11. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
12. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/ β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13.
13. Fowler J, Chappell R, Ritter M. Is α/β for prostate cancer really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
14. Wang JZ, Guerrero M, Li XA. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;55:194-203.
15. Wang JZ, Li XA, Yu CX, et al. The low α/β ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 2003;57:1101-8.
16. Fowler JF, Ritter MA, Fenwick JD, et al. How low is the α/βl ratio for prostate cancer? In regard to Wang et al. [letter]. Int J Radiat Oncol Biol Phys 2003;57:593-5.
17. Wang JZ, Guerrero M, Li XA. Low α/β ratio for prostate cancer: in response to Dr. Fowler et al. [letter]. Int J Radiat Oncol Biol Phys 2003;57:595-6.
18. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia. into tumor local control modeling of prostate cancer: Implications for the α/βl ratio. Int J Radiat Oncol Biol Phys 2003;57:391-401.
19. Kal HB, Van Gellekom MPR. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;57:1116-21.
20. Carlone M, Wilkins D, Nyiri B, et al. Comparison of α/β estimates from homogeneous (individual) and heterogeneous (population) tumor control models for early stage prostate cancer. Med Phys 2003; 30:2832-48.
21. Dasu A, Fowler JF. Comments on 'Comparison of in vitro and in vivo α/ βl ratios for prostate cancer'. Phys Med Biol 2005;50:L1-4.
22. Wang JZ, Stewart RD, Carlson DJ, et al. Reply to "comments on 'comparison of in vitro and in vivo α/β ratios for prostate cancer'". Phys Med Biol 2005;50: L5-8.
23. Levegrün S, Jackson A, Zelefsky MJ, et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. Int J Radiat Oncol Biol Phys 2001;51:1064-80.
24. King CR, Mayo CS. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact? [letter]. Int J Radiat Oncol Biol Phys 2000;47:536-8.
25. Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumor control. Phys Med Biol 2003;48:139-55.
26. Wang JZ, Li XA. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys 2003;30:34-40.
27. Perez CA, Michalski J, Mansur D, et al. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Cancer, J 2004;10:349-56.
28. Wang JZ, Mayr NA, Li XA, et al. Modeling prostate cancer: in regard to Nahum et al. [letter]. Int J Radiat Oncol Biol Phys 2005;61:309-10.
29. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-28.
30. Haustermans K, Fowler JF. A comment on proliferation rates in human prostate cancer [letter]. Int J Radiat Oncol Biol Phys 2000;48:303.
31. Jones B, Cominos M, Dale RG. Application of biological effective dose (BED) to estimate the duration of symptomatic relief and repopulation dose equivalent in palliative radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2003;55:736-42.
32. Porter EH. The statistics of dose/cure relationships for irradiated tumors. Br J Radiol 1980;53:210-27.
33. Buffa FM, West C, Byrne K, et al. Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: the significance of hypoxia on tumor control modeling. Int J Radiat Oncol Biol Phys 2001;49: 1109-18.
34. Hendry JH, Thames HD. Fractionation sensitivity and the oxygen effect. Br J Radiol 1990;63:79-80.
35. Popple RA, Ove R, Shen S. Tumor control plobability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54:921-7.
36. Zolzer F, Streffer C. Increased radiosensitivity with chronic hypoxia. in four human tumor cell lines. Int J Radiat Oncol Biol Phys; 2002;54:910-20.
37. Watts ME, Hodgkiss RJ, Jones NR, et al. Radiosensitization of Chinese hamster cells by oxygen and misonidazole at low X-ray doses. Int J Radiat Biol 1986;50:1009-21.
38. Skarsgard LD, Harrison I, Durand RE. The radiation response of asynchronous cells at low dose: evidence of substructure. Radiat Res 1991;127:248-56.
39. Speke AK, Hill RP. The effects of claiming and reoxygenation on repopulation during fractionated irradiation. Int J Radiat Oncol Biol Phys 1995;31:857-63.
40. Hill RP, FyIes W, Milosevic M, et al. Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int J Radiat Biol 2003;79:487-94.
41. Brenner DJ, Hlatky LR, Hahnfeldt PJ, et al. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys 1995;32:379-90.
42. Jones B, Dale G. Estimation of tumor hypoxia. fraction from clinical data sets compatible with accelerated repopulation. Acta Oncologica 1998;37:263-8.
43. Brenner DJ, Hall EJ. In. response to Drs. King and Mayo: Low α/ β values for prostate appear to be independent of modeling details [letter]. Int J Radiat Oncol Biol Phys 2000;47:2753-65.
44. Li XA, Wang JZ, Stewart RD, et al. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Phys Med Biol 2003;48:2753-65.
45. Stock RG, Stone NN, Tabert A, et al. A dose-response study for 1-125 prostate implants. Int J Radiat Oncol Biol Phys 1999;41:101-8.